Infinity Pharmaceuticals

NCT00113204

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

NCT00276302

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

NCT00606814

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

NCT00724425

A Phase 1 Dose Escalation Study of IPI-493

NCT00761696

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

NCT01193491

Dose Escalation of IPI-493 in Hematologic Malignancies

NCT01383538

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

NCT01871675

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

NCT02598570

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

NCT02637531

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02640833

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

NCT03719326

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies